Skyrizi (risankizumab)

£2,467.50£2,667.50

Skyrizi (risankizumab) is a medication used to treat adults with Plaque Psoriasis and Psoriatic Arthritis.

DISEASE INDICATIONS

Psoriasis

MANUFACTURER

AbbVie Ltd

USAGE

Subcutaneous

MEDICINE APPROVED BY

  • European Medical Agency (EMA)

  • Food and Drug Administration (FDA)

  • Therapeutic Goods Administration (TGA)

    PATIENTS HELPED

    • Over 1.2 million patients reached

    • More than 11,000 patients helped

    • 100% successful deliveries to 88 countries

This content has been reviewed by a Medical Doctor.
SKYRIZI (RISANKIZUMAB) Package

Pre-filled syringe of 150 mg/ml, Pre-filled pen of 150 mg/ml

Reviews

There are no reviews yet.

Be the first to review “Skyrizi (risankizumab)”

Your email address will not be published. Required fields are marked *

Shopping Cart